By addressing both microbial dysbiosis and metabolic dysfunction, SS offers a novel therapeutic strategy for T2D management, emphasizing the interplay between gut microbiota, inflammation, and insulin sensitivity. This evidence concerns the gene INS and type 2 diabetes mellitus.